Radicava’s Real-world Safety Profile Matches Clinical Trial Data: Study
Using the approved treatment Radicava (edaravone) in a real-world setting resulted in a similar safety profile as that reported…
Articles by Marisa Wexler, MS
Finding TDP-43 Clumps in Muscle Biopsies May Speed Diagnosis
Doing a muscle biopsy to look for abnormal clumps of the TDP-43 protein in the nerve fibers of muscle tissue…
ILB Safe, Shows Potential to Slow ALS Progression in Small Phase 2 Trial
TikoMed reported that ILB, its investigational therapy to protect nerve cells in amyotrophic lateral sclerosis (ALS), was well-tolerated by patients, and…
Radicava ORS Shows Safety, Tolerability Over Nearly Year of Use
Radicava ORS, an oral formulation of edaravone recently approved to treat amyotrophic lateral sclerosis (ALS) in the U.S.,…
Albrioza, Oral ALS Therapy Known as AMX0035, Approved in Canada
Albrioza, formerly called AMX0035, has been given conditional approval by Health Canada for the treatment of amyotrophic lateral…
CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests
Treatment with the experimental gold nanocrystal therapy CNM-Au8 decreased the risk of mortality by 64% among people with early…
Clinical Trials in Pediatric ALS ‘Simply Not Feasible,’ Scientists Argue
The rarity of amyotrophic lateral sclerosis (ALS) in children makes it impossible to realistically conduct clinical trials of experimental…
AMX0035 Prolonged Time to Ventilation, Tracheostomy in CENTAUR Trial
Treatment with AMX0035 significantly prolonged the time that people with amyotrophic lateral sclerosis (ALS) in the CENTAUR clinical…
Team Gleason, Synchron Unite to Advance Stentrode Device for ALS
Team Gleason and Synchron have entered into a partnership aiming to advance a technology that offers greater accessibility…
Lead Antibody Targeting Toxic TDP-43 Protein to Advance, ProMIS Says
ProMIS Neurosciences announced plans to advance a monoclonal antibody against toxic TDP-43 protein clumps as a potential treatment for amyotrophic lateral…